Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskNeutral

Vaxcyte, Inc.

Filed: Jun 15, 2026CIK: 0001649094
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Vaxcyte, Inc. held its Annual Meeting of Stockholders on June 15, 2026, where shareholders elected three Class III directors to serve until the 2029 Annual Meeting. This routine governance event reflects the company's commitment to maintaining effective leadership and management continuity.

Key Takeaways

Three Class III director nominees were elected at the Annual Meeting of Stockholders held on June 15, 2026

The elected directors will serve until the 2029 Annual Meeting or until their successors are duly elected

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJun 15, 2026
Item5.02
CategoryExecutive Change
CIK0001649094
Accession #pcvx-20260615
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
board change

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings